follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Par Pharma gets OK for generic version of Luvox

By

Back to Top Comments Email Print

Latest News

advertisement

Par Pharmaceutical Cos. Inc. on Thursday announced it has received final approval from the Food and Drug Administration for its abbreviated new drug application for a generic version of Jazz Pharmaceuticals' Luvox CR.

According to an announcement from Par, in Woodcliff Lake, the drug is indicated for the treatment of obsessive compulsive disorder. The company has been awarded 180 days of marketing exclusivity on its generic version.

According to IMS Health data cited in the release, annual U.S. sales of Luvox CR are approximately $51 million.

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top